论文部分内容阅读
目的:研究双环醇片在乳腺癌化学治疗过程中防治肝损害的作用。方法:选择确诊乳腺癌行化疗患者98例,随机分为观察组与对照组,每组49例。予FEC方案或TE方案化疗,观察组予双环醇片护肝治疗,对照组则不予药物护肝,比较两组ALT、AST、ALP、TBIL等肝功能指标及药物性肝损伤发生情况。结果:观察组乳腺癌化疗联合应用双环醇片后药物性肝损伤发生率为6.1%(3/49),对照组则为24.5%(12/49),两组比较差异有统计学意义(χ2=6.376,P=0.011)。观察组乳腺癌化疗联合应用双环醇片前ALT、AST、ALP、TBIL等肝功能指标与对照组分别相比较,差异均无统计学意义(P>0.05);治疗后ALT、AST、ALP、TBIL等肝功能指标与对照组分别相比较,差异均有统计学意义(P<0.05)。观察组乳腺癌化疗前后ALT、AST、ALP、TBIL等肝功能指标分别相比较,差异均无统计学意义(P>0.05);对照组乳腺癌化疗前后ALT、AST、ALP、TBIL等肝功能指标分别相比较,差异均有统计学意义(P<0.05)。结论:双环醇片在乳腺癌化疗过程中能够防止肝功能指标异常、降低药物性肝损伤的发生。
Objective: To study the role of bicyclol tablets in preventing and treating liver damage during the chemotherapy of breast cancer. Methods: A total of 98 patients with breast cancer who underwent chemotherapy were randomly divided into observation group and control group, with 49 cases in each group. The patients in the observation group were treated with bicyclol tablets and the control group were not given drug liver protection. The liver function indexes such as ALT, AST, ALP, TBIL and the incidence of drug-induced liver injury in the two groups were compared. Results: The incidence of drug-induced liver injury was 6.1% (3/49) in the observation group and 24.5% (12/49) in the control group, with significant differences between the two groups (χ2 = 6.376, P = 0.011). There was no significant difference in ALT, AST, ALP, TBIL and other liver function indexes between the observation group and the control group before chemotherapy (P> 0.05). ALT, AST, ALP and TBIL The liver function indexes were significantly different from those in the control group (P <0.05). The liver function indexes of ALT, AST, ALP and TBIL in the observation group before and after chemotherapy were not significantly different (P> 0.05). The liver function indexes such as ALT, AST, ALP and TBIL in the control group before and after chemotherapy Respectively, the differences were statistically significant (P <0.05). CONCLUSION: Bicyclol can prevent abnormal liver function and reduce the incidence of drug-induced liver injury during chemotherapy of breast cancer.